In the company’s news Friday,
Neoprobe Corporation announced that the European Medicines Agency (EMEA) has approved their RIGScan® CR cancer detection system for additional testing and development, leading to the potential approval for Neoprobe to market the product throughout the European Union (EU) and affiliated countries.
The EMEA controls the introduction, development, and marketing of medical devices and products in the EU. Neoprobe’s concept for the RIGScan® CR system is a combination of radiation-emitting antibodies with a detection device to assist surgeons in the discovery of tumor deposits that may not be observable by conventional methods.
The company believes it has gotten tangible guidance from the EMEA on how to best continue the design of RIGScan® CR. Furthermore, the EMEA allowed for early termination of additional testing depending on the results. “We are excited by the response from the EMEA,” said David Bupp, Neoprobe’s President and CEO. He noted that the EMEA’s “response provides a clear, achievable development pathway for RIGScan® CR.”
Importantly, he said, “[t]he response acknowledges that the technology meets a currently unmet medical need and has the potential for improving the long term prognosis for both primary and recurrent colorectal patients. The EMEA has suggested a mechanism for an early termination of the study if, as anticipated, early improved outcomes are observed in the RIGScan treatment arm versus the control arm patients.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
